AR030037A1 - Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo - Google Patents

Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo

Info

Publication number
AR030037A1
AR030037A1 ARP000106197A ARP000106197A AR030037A1 AR 030037 A1 AR030037 A1 AR 030037A1 AR P000106197 A ARP000106197 A AR P000106197A AR P000106197 A ARP000106197 A AR P000106197A AR 030037 A1 AR030037 A1 AR 030037A1
Authority
AR
Argentina
Prior art keywords
fertility
hormones
control
estrogen
administration system
Prior art date
Application number
ARP000106197A
Other languages
English (en)
Original Assignee
Levotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levotech Inc filed Critical Levotech Inc
Publication of AR030037A1 publication Critical patent/AR030037A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un sistema de administracion de anticonceptivos transdérmico mejorado del tipo que comprende una capa de soporte que es sustancialmente impermeable a las hormonas de estrogeno y progestina que controlan la fertilidad, para ser administrado transdérmicamente y una matriz polimérica adhesiva fija a la capa de soporte, donde la mejora comprende ingredientes del soporte que consisten, en una base de porcentaje en peso, de aproximadamente 0 a aproximadamente 10% de humectante/plastificante, de aproximadamente 10 a aproximadamente 60% de una combinacion de agentes que mejoran la permeacion a la piel, que es una mezcla que comprende a sulfoxido de dimetilo, un éster de alcohol graso de C8-20 de ácido láctico, un éster de alquilo inferior C1-4 de ácido láctico y ácido cáprico presentes en una porcion que fluctua de aproximadamente 6:1:1:0.8 y una cantidad efectiva para controlar la fertilidad de hormonas de estrogeno y progestina en donde tales hormonas proporcionan por lo menos dosis diarias efectivas de 20 mcg/día para levonorgestrel y 10 a 50 mcg/día para etinil estradiol. Uso de a) una capa de soporte que es sustancialmente impermeable a las hormonas de estrogeno y progestina que controlan la fertilidad a ser administrada transdermicamente; (b) una matriz polimérica adhesiva fija a la capa de soporte que comprende, en una base de porcentaje en peso, de aproximadamente 0% a aproximadamente 10% de humectante/plastificante, de aproximadamente 30 a aproximadamente 60% de una combinacion de agentes que mejoran la permeacion a la piel que es una mezcla que consiste de sulfoxido de dimetilo, un éster de ácido láctico de alcohol graso C8-20, un alquil éster inferior (C1-4) de ácido láctico y ácido cáprico presente en una proporcion de aproximadamente 2.0:1:1:0.8 a aproximadamente 6:1:1:0.8 respectivamente y una cantidad efectiva de hormonas de estrogeno y progestina que controlan la fertilidad, en donde tales hormonas proporcionan por lo menos mínimas dosis diarias efectivas de tales hormonas para efectuar el control de la fertilidad, para proporcionar por lo menos las mínimas cantidades de dosis efectivas de levonorgestrel y etinil estradiol por aproximadamente las primeras tres semanas de ciclo menstrual por ciclos menstruales sucesivos por un período que se extiende hasta donde se desea el control de la fertilidad, que es para la fabricacion de un sistema de administracion de anticonceptivo transdérmico para controlar la fertilidad mediante la aplicacion a la piel de un sujeto que desea tal tratamiento.
ARP000106197A 1999-11-24 2000-11-23 Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo AR030037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16753599P 1999-11-24 1999-11-24

Publications (1)

Publication Number Publication Date
AR030037A1 true AR030037A1 (es) 2003-08-13

Family

ID=22607771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106197A AR030037A1 (es) 1999-11-24 2000-11-23 Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo

Country Status (21)

Country Link
EP (1) EP1242012B1 (es)
JP (2) JP4841781B2 (es)
KR (1) KR100758757B1 (es)
CN (1) CN1399533A (es)
AR (1) AR030037A1 (es)
AT (1) ATE453374T1 (es)
AU (2) AU784196B2 (es)
BR (1) BR0015802B1 (es)
CA (1) CA2391430C (es)
CY (1) CY1110615T1 (es)
DE (1) DE60043621D1 (es)
DK (1) DK1242012T3 (es)
ES (1) ES2338860T3 (es)
IL (1) IL149655A0 (es)
MX (1) MXPA02005224A (es)
NO (1) NO331218B1 (es)
NZ (1) NZ518723A (es)
PT (1) PT1242012E (es)
TW (1) TWI253350B (es)
WO (1) WO2001037770A1 (es)
ZA (1) ZA200203525B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
EP1594483B1 (de) 2003-02-21 2006-07-19 Schering AG Uv-stabiles transdermales pflaster
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
EP1682061B1 (en) * 2003-10-28 2017-03-15 Noven Pharmaceuticals, Inc. Transdermal drug delivery device
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US20050202073A1 (en) 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
CN1313084C (zh) * 2004-11-05 2007-05-02 郑会义 一种透皮避孕药传送体系及制备方法
CN1318032C (zh) * 2005-01-24 2007-05-30 浙江大学 炔雌醇透皮吸收贴片
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20080075779A1 (en) * 2006-09-27 2008-03-27 Chappa Ralph A Additives And Methods For Enhancing Active Agent Elution Kinetics
GB0809905D0 (en) * 2008-06-02 2008-07-09 Secr Defence A Transdermal drug delivery device
US20120263784A1 (en) 2009-10-12 2012-10-18 Lyka Labs Limited Emergency contraceptive
CN103025320A (zh) * 2010-03-28 2013-04-03 伊万斯彻有限公司 阴道内药物递送装置
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
WO2013067346A1 (en) * 2011-11-04 2013-05-10 Agile Therapeutics, Inc. Dermal delivery compositions and methods
EA030797B1 (ru) * 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система трансдермальной доставки гормонов (варианты) и способы ее применения
US9314470B2 (en) 2012-12-28 2016-04-19 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632740A (en) * 1968-06-13 1972-01-04 Johnson & Johnson Topical device for the therapeutic management of dermatological lesions with steroids
JPS5843368B2 (ja) * 1980-10-30 1983-09-27 日東電工株式会社 消炎鎮痛貼付剤
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5750137A (en) * 1993-09-29 1998-05-12 Taskovich; Lina Tormen Monoglyceride/lactate ester permeation enhancer
ATE220911T1 (de) * 1994-11-17 2002-08-15 Toray Industries Transdermal absorbierbare zubereitung
CA2222133C (en) * 1995-06-07 2002-12-24 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process

Also Published As

Publication number Publication date
PT1242012E (pt) 2010-03-31
IL149655A0 (en) 2002-11-10
AU784196B2 (en) 2006-02-23
NO20022420D0 (no) 2002-05-22
ES2338860T3 (es) 2010-05-13
DK1242012T3 (da) 2010-04-26
CA2391430C (en) 2009-10-06
NO20022420L (no) 2002-07-18
EP1242012A4 (en) 2006-05-31
DE60043621D1 (de) 2010-02-11
KR20020072280A (ko) 2002-09-14
TWI253350B (en) 2006-04-21
CN1399533A (zh) 2003-02-26
AU2006201918B2 (en) 2009-07-30
ATE453374T1 (de) 2010-01-15
ZA200203525B (en) 2003-07-18
JP2003533434A (ja) 2003-11-11
BR0015802B1 (pt) 2014-04-29
JP4841781B2 (ja) 2011-12-21
NO331218B1 (no) 2011-11-07
JP2011231125A (ja) 2011-11-17
CY1110615T1 (el) 2015-04-29
CA2391430A1 (en) 2001-05-31
EP1242012A1 (en) 2002-09-25
MXPA02005224A (es) 2003-09-25
AU1788301A (en) 2001-06-04
EP1242012B1 (en) 2009-12-30
AU2006201918A1 (en) 2006-06-01
WO2001037770A1 (en) 2001-05-31
BR0015802A (pt) 2003-06-24
KR100758757B1 (ko) 2007-09-14
NZ518723A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
AR030037A1 (es) Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo
KR100392435B1 (ko) 성스테로이드를함유하는경피치료시스템
AU679557B2 (en) Low flux transdermal potent drug delivery system
RU2176499C2 (ru) Композиция для чрескожного введения стероидных лекарственных средств и содержащий ее препарат
US5453279A (en) Enhancing transdermal absorption compositions; transdermal dosage form; and process
KR100561255B1 (ko) 호르몬 방출용 트랜스더멀 치료 시스템
ITMI961152A1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
JP2014051507A (ja) 避妊及びホルモン補充のためのノルエルゲストロミンを含む経皮治療システム
KR880701114A (ko) 에스트라디올 및 기타 에스트로겐성 스테로이드용 경피 흡수 투여단위 및 그 투여방법
CZ291656B6 (cs) Transdermální terapeutický systém ve formě náplasti obsahující estradiol a způsob jeho výroby
ATE307569T1 (de) Gelierbare pharmazeutische zusammensetzungen
CN104936582B (zh) 用于激素和其他药剂的经皮传送的组合物和方法
JP2009512658A5 (es)
PT95245B (pt) Sistema de matriz solida para a libertacao transdermica de farmacos
JPH08500584A (ja) ３−ケト−デソゲストレルを含有する経皮適用剤
CN102858372A (zh) 皮肤刺激抑制剂和经皮吸收制剂
CN101700246A (zh) 复合避孕组合物以及含有该组合物的避孕透皮贴剂及制法
CZ284034B6 (cs) Lanolinové deriváty jako látky podporující penetraci
CN101843603B (zh) 无需渗透促进剂的激素透皮传递
TWI343259B (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
CN1913878B (zh) 无需渗透促进剂的激素透皮传递
JPH09508911A (ja) デソゲストレルを含有する経皮適用剤
JP2852816B2 (ja) 溶解剤および該溶解剤を含有する外用製剤
CN101695483B (zh) 能独立控制的含有孕激素和雌激素的避孕透皮贴剂及制法
KR100438254B1 (ko) 비타민 ｄ 유사체를 포함하는 매트릭스형 경피흡수제제

Legal Events

Date Code Title Description
FC Refusal